A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease
Authors:
- 16 September 2007
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 30 (5) , 768-782
Abstract
Summary: Type III Gaucher disease is one of the three recognized subtypes of Gaucher disease, an inherited deficiency of lysosomal glucocerebrosidase. Phenotypically there is a wide spectrum of visceral and neurological manifestations. Enzyme replacement is effective in managing the visceral disease; however, the neurological manifestations remain a more challenging obstacle. There is an unfulfilled need to reliably monitor neurological disease and its response to treatment. A severity scoring tool was developed through neurological domain identification, item generation and tool formation. Domain identification was established based on a retrospective single centre study (n=15) and a systematic review of publications. Forty‐seven patients with neuronopathic Gaucher disease were then assessed using the tool to establish the clinical and statistical reliability of each domain. Judgement quantification of the tool was established through a process of content validity involving five European experts. Content validity is considered to be most effective when undertaken systematically. Concurrent validity and feasibility of the tool was also highlighted. This process allowed a revised and validated version of the tool to be developed.Keywords
This publication has 24 references indexed in Scilit:
- Establishing content validity of the oral assessment guide in children and young peopleEuropean Journal of Cancer, 2006
- Ten years’ experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher diseaseActa Paediatrica, 2006
- Ten years’ experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher diseaseActa Paediatrica, 2006
- A Constipation Assessment Scale for Use in Pediatric OncologyJournal of Pediatric Oncology Nursing, 2006
- Enzyme replacement therapy for Gaucher disease in AustraliaInternal Medicine Journal, 2005
- Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutationsAmerican Journal of Medical Genetics, 2002
- Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials.Annals of the Rheumatic Diseases, 1996
- Enzyme Infusion Therapy of the Norrbottnian (Type 3) Gaucher DiseaseNeuropediatrics, 1995
- Questionnaire Design, Interviewing and Attitude MeasurementJournal of Marketing Research, 1993
- Scale Development: Theory and Applications.Contemporary Sociology: A Journal of Reviews, 1992